CIMT and taVNS for Hemiplegia in Infants
Study Details
Study Description
Brief Summary
Newborns who are born premature or suffer brain injury at birth are at risk for motor problems that may cause weakness in reaching and grasping on one side of the body. In older children, therapists may use a hand mitt and restraint for the stronger arm, to encourage use of the weaker side, called constraint-induced movement therapy (CIMT). Even with the high intensity therapy of CIMT, it typically takes between 40-120 hours total treatment time for most children to improve their motor skills. A non-invasive form of nerve stimulation, transcutaneous auricular vagus nerve stimulation (taVNS), stimulates a nerve by the ear that enhances learning motor skills. The purpose of this study is to evaluate the safety and effectiveness of taVNS to improve motor skills when paired with CIMT in infants with one-sided weakness at 6-18months of age.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Early Phase 1 |
Detailed Description
Recent pioneering studies have used neuromodulation combined with intensive motor therapies in adults after stroke. Few studies have investigated combining neuromodulation and evidence-based pediatric intensive therapies such as CIMT, and then only in older children with CP to enhance neuroplasticity and improve functional outcomes. The investigators are the first to use non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) paired with a motor task of bottle-feeding in infants with feeding failure. taVNS paired with motor feeding activity was safe and over 50% infants attained full oral feeds who were slated to receive a gastrostomy tube (G-tube). With the unique collaboration of experts in brain stimulation, pediatric translational clinical science and pediatric occupational therapy in this pilot project, the investigators propose to expand the paradigm of pairing neuromodulation with motor training in at-risk infants by exploring the safety, feasibility, and effectiveness of delivering taVNS concurrently with CIMT. The hypothesis is that combining taVNS with intensive CIMT may boost neuroplasticity, allowing for delivery of infant therapy at a minimally effective dosage while improving infant outcomes.
The investigators aim to determine the feasibility and safety of taVNS in at-risk infants 6-18mo undergoing CIMT therapy in open label pilot trial and assess both infant tolerability and the therapist's ability to deliver high-quality CIMT along with taVNS.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: CIMT + taVNS The investigators will deliver taVNS paired with 40h of Constraint Induced Movement Therapy for unilateral weakness/hemiplegia |
Device: transcutaneous auricular vagus nerve stimulation
Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
Other Names:
Other: Constraint induced movement therapy
Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
Other Names:
|
Outcome Measures
Primary Outcome Measures
- CIMT fidelity [0-1 month]
Feasibility of delivering high fidelity CIMT therapy sessions while the therapist is also triggering taVNS using the Fidelity of Implementation Measure (FIRM) with scoring range (0-4), higher scores indicate greater consistency of therapy with established CIMT procedure
- Quality of Upper Extremity Skills Test (QUEST) [0-2 months]
test of hand function and quality of movement between the right and left sides of the body, scoring range 0-100, higher scores indicate better hand function
Secondary Outcome Measures
- Developmental Assessment of Young Children (DAYC) Physical Development domain [0-2 months]
Developmental Assessment of Young Children, 2nd edition, physical domain is a standardized assessment of fine and gross motor skills, with a mean of 100 +/- 15
- Goal Attainment Scale (GAS) [0-2 months]
Goal Attainment Scale is an individualized standardized outcome measure that calculates the extent to which a patient's individual therapy goals are met, scored from -2 to +2 with higher scores indicating better than expected outcome, -2 indicating worse than expected outcome
- Gross Motor Function Measure-66 (GMFM-66) [0-2 months]
Gross Motor Function Measure-66 scores range from 0-3, with higher scores indicating better foundational gross motor skills and greater mastery of a task
Eligibility Criteria
Criteria
Inclusion Criteria:
Must have all of the following:
-
6-18 month-old infants with hemiplegia/motor asymmetry
-
Must be able to participate in high intensity CIMT
-
Gross Motor Function Classification System (GMFCS) level I-IV
Exclusion Criteria:
Must have none of the following:
-
GMFCS level V
-
severe motor impairment/quadriplegic involvement
-
uncorrected blindness or deafness
-
cardiomyopathy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
Sponsors and Collaborators
- Medical University of South Carolina
- National Center for Neuromodulation for Rehabilitation
- National Institutes of Health (NIH)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 109558
- P2CHD086844